Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2020 08:00 ET | Source: InCrowd, Inc

US Physicians Aren’t Confident About US Coronavirus Preparedness, According to InCrowd Data

WATERTOWN, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- As the number of US novel coronavirus (now named COVID-19) cases increase, US physicians report a lack of confidence in their preparedness to...
January 30, 2020 08:15 ET | Source: Families Fighting Flu

Flu Activity at “High Levels” Nationwide as Americans Stress About Coronavirus

Arlington, Virginia, Jan. 30, 2020 (GLOBE NEWSWIRE) -- The Centers for Disease Control and Prevention (CDC) has confirmed five cases of Coronavirus in the U.S. as of January 29, 2020, while there...
February 09, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)

PHILADELPHIA, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and...
October 19, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
February 02, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study

PHILADELPHIA, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the results of a new efficacy study of Ampligen® in a...
October 20, 2014 12:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola

PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government...
September 29, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators

PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
September 08, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
August 11, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014

PHILADELPHIA, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the six months ended June 30, 2014. The net loss (including non-cash effects) was...
August 04, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses

PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...